Shares of uniQure NV (QURE) are soaring 5.47% in pre-market trading on Friday following the release of the company's first-quarter 2025 financial results. The gene therapy company reported a smaller-than-expected loss, beating analyst estimates and boosting investor confidence.
uniQure announced a quarterly adjusted loss of 82 cents per share, significantly better than the mean expectation of a $1.01 loss per share from twelve analysts. This performance marks an improvement from the same quarter last year when the company reported a loss of $1.36 per share. However, revenue fell 81.5% to $1.57 million, falling short of the $6.27 million analysts had expected.
Despite the revenue decline, investors appear to be focusing on the company's ability to narrow its losses. The positive sentiment is further bolstered by strong analyst recommendations, with 12 out of 14 analysts rating the stock as "strong buy" or "buy." Wall Street's median 12-month price target for uniQure NV stands at $30.00, suggesting significant upside potential from current levels. The biotechnology sector as a whole is also receiving "buy" recommendations, indicating a favorable outlook for companies like uniQure operating in this space.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.